HEALTH TECHNOLOGY

Alkem Laboratories Ltd. to Launch State of the Art Technology for Diabetic Foot Ulcer Management

Alkem Laboratories Ltd. | January 13, 2022

Alkem Laboratories Ltd. (Alkem) hereby announces to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval. This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India.

India currently has approximately 77 mn diabetes patients, the second highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes. Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead to limb amputation within 6–18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes. Alkem has collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient's quality of life and the associated economic burden on the healthcare system.

"In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers."

Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd

Adding further, Mr. Sandeep asserted, "Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives."

About Alkem Laboratories Ltd

Established in 1973 and headquartered in Mumbai, Alkem is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company also has presence in more than 40 international markets, with the United States being its key focus market.

Spotlight

Women’s Health Week is May 14 to 20. In honor of this celebration of women, Vonda Wright, MD, UPMC Center for Sports Medicine orthopedic surgeon, is providing her recommendations on how to live well in each decade of your life. Whether you are in your twenties, thirties, forties or beyond, these health tips will help you get on a better track. Women in the United States live 81 years on average, almost five years longer than men. Our bodies and minds are made to carry us for many productive decades-to school, to work, and to give birth to babies and raise families.

Spotlight

Women’s Health Week is May 14 to 20. In honor of this celebration of women, Vonda Wright, MD, UPMC Center for Sports Medicine orthopedic surgeon, is providing her recommendations on how to live well in each decade of your life. Whether you are in your twenties, thirties, forties or beyond, these health tips will help you get on a better track. Women in the United States live 81 years on average, almost five years longer than men. Our bodies and minds are made to carry us for many productive decades-to school, to work, and to give birth to babies and raise families.

Related News

HEALTH TECHNOLOGY

Ver 2.0 of Hospital Purchased Services Technology Invoice Reconciliation Launched

VIE Healthcare | February 16, 2021

To provide data analytics, identify cost reductions, and to automate the reconciliation of hospital purchased services invoices, VIE Healthcare Consulting has a launched Invoice ROI 2.0 technology. VIE Healthcare Consulting has launched a new update on a proven technology with the aim of examining hospital purchased services invoices for identifying overcharges and inaccuracies. reconciliation process is automated by Invoice ROI. This new update has enhanced patents and features, which is capable of generating millions of dollars The launch has taken place based on the knowledge and experience of Lisa Miller, who has previously developed a technology for identifying expense reduction opportunities. Purchased services invoices denote 45-50 % of US healthcare system and hospital non-labor expenses. Invoices for purchased services area sort of time-consuming manual authentication as hospital monetary managers and branch managers inspect charges for agreement pricing mistakes and overbilling. Invoice ROI excerpts line item particulars and settles invoices. The technology classifies cost discounts from off-contract charges or imprecisions, for example from erroneously applied votive terms. The technology also mixes with analytics and benchmarking gears and provides data imagining. Use of Invoice ROI consequences in intended line-by-line discounts in charges that can notify bill pay, bond negotiations, RFPs, and planned financial organization. Hospital CFOs face unique challenges related to purchased services, which are billed after they are provided, as distinct from buying medical equipment or supplies. Healthcare costs are tremendously mutable and complex, reliant on on mismatched systems, and subject to complicated contractual terms. Extreme fees, billing errors, manual dispensation costs, and off-contract expenditure are among the economic challenges that health care administrations face. Adding to a modified database, the system makes reports that can be used to improve the supply chain, money or direct to vendors. By recording overcharges, the Bill ROI automated settlement tool supports revenue improvement and margin development for healthcare systems and hospitals.

Read More

HEALTH TECHNOLOGY

FINVASIA Acquires Gini Health, a health-tech company, and expands Into Healthcare Services

FINVASIA | November 01, 2021

FINVASIA, today, announced its investment in Gini Health, a Canada based healthcare technology company that pioneered DNA and lifestyle data based personalized health to prevent diseases. This acquisition furthers FINVASIA’s strategic business objectives of investing in traditional business and transforming them. The partnership supports FINVASIA’s commitment to health care to accelerate technology-led innovation in preventive and personalized healthcare services.Effective immediately, all the previous investors have exited, making FINVASIA and Gini Health’s founder and CEO Gurjot Narwal key stakeholders in the company. This move by FINVASIA is a step towards making the company’s capital structure lean, providing them more room to support their business strategy. Gini Health’s founder and CEO Gurjot Narwal will keep leading the company. Finvasia along with the investment will provide group resources, operational experience, technology, infrastructure, and its reach as a multidisciplinary, multinational organization. “We’re excited to partner with Gini Health and this investment is a cornerstone of our strategy to fuel our pipeline with healthcare innovation. Together, we’ll bring tech driven personalised and long-term health care to people at a time when health is top-of-mind for all of us. This investment executes on FINVASIA’s commitment to transform healthcare access and delivery.” Sarvjeet Singh, Co-founder Finvasia It’s been an impressive year and half for FINVASIA, with its robust investments in many diverse sectors including financial services, fintech and healthcare. Given the global interest in healthcare services post COVID, Gini Health has been one of the most significant areas of investment for the group. “Health industry is going through a massive transformation and Gini Health has been leading this with its approach to use health data and technology to empower users to get positive health outcomes,” said Gurjot Narwal, CEO & Founder Gini Health. “FINVASIA is a successful conglomerate that harnesses technology to drive innovation and transform industries. Partnering with FINVASIA brings two passionate and innovative companies together to accelerate transformation in healthcare at a global level,” he added. “With this deal, we have got investment and resources to write the next chapter of growth and innovation. Stay tuned for our big new product announcements.” About FINVASIA Finvasia is a global enterprise that owns multiple brands in financial services, fintech, blockchain, real-estate, healthcare and technology sectors. The group invests in technology-oriented businesses and products and is committed to drive sustainable development and generate a positive impact with its businesses. Finvasia, along with its subsidiaries and sister concerns, is registered with a gamut of regulatory bodies across the world in various capacities. About Gini Health Gini Health is a Canada based health-tech company that serves customers across North America and Europe. Gini Health has received various awards and accolades for its personalized healthcare approach in preventive health care. Gini was invested by global VCs like TechStars, Rangle, Uken among others. It has grown into a digital healthcare services company with the launch of its first chronic healthcare management program.

Read More

HEALTH TECHNOLOGY

maiData and inContext.ai Ink a Memorandum of Understanding How Two Healthcare AI Companies Plan to Work

maiData | November 12, 2020

maiData Corporation and inContext.ai today declared fulfillment of a Memorandum of Understanding (MOU) that traces how the two medical services AI organizations intend to cooperate to quicken AI development and arrangement. Under the details of the MOU, maiData will coordinate Natural Language Processing (NLP) innovation from inContext.ai into its maiVA programming, which maiData with then use to recognize semantically applicable subsets of clinical information for pseudonymization, extraction and conveyance to clients. The expansion of NLP innovation from inContext.ai into maiVA programming will permit maiData clients to indicate more refined inquiry and surmising standards, and will give more nuanced, interoperable details about the clinical information that is gathered. “The integration of the inContext.ai technology into our platform will allow us to rapidly locate the data desired by our customers from within medical reports. It will increase the precision with which we can locate the exact data that our customers require,” said Julian Marshall, CEO of maiData. “This will be the most streamlined approach to medical data collection that our customers have ever known.” Robert Grzeszczuk, CEO of inContext.ai, said “Our company is excited to have been selected by maiData to provide our Natural Language Processing technology. Our deep experience in general language understanding will help maiData deliver targeted clinical information to the AI developers, Contract Research Organizations (CROs) and Pharmaceutical companies that they serve.” maiData has built up a smoothed out way to deal with information assortment that will extraordinarily decrease the difficulties related with customary strategies for curating information for the turn of events and testing of clinical AI calculations. Filling in as the extension between clinical information sources and clinical AI designers, maiData quickens AI advancement and organization. inContext.ai creates intellectual innovation and apparatuses that smooth out conveyance of patient consideration and reduction clinical blunders by helping clinicians center around what they excel at: thinking about patients. Execution of inContext.ai's Deep Artificial Intelligence (AI) apparatuses supporting Natural Language Processing (NLP) undertakings including Question Answering (QA), Reading Comprehension (RC), and Natural Language Inference (NLI), which consistently synchronize with EHR frameworks, implies medical services suppliers remain in consistence with clinical/lawful/administrative obligations, fundamentally improve cost, quality, and admittance to mind. About maiData Corporation: maiData Corporation is a new Silicon Valley startup company. maiData fulfills its mission of “Bringing A.I. to Life” by focusing on helping developers improve the quality and generalizability of their algorithms and helping CROs expand the scale of the clinical studies they can perform. About inContext.ai: inContext.ai is a premier natural language processing AI company based in Houston whose technologies help medical providers and companies leverage the rich data in medical reports in new ways. InContext.ai’s research is funded in part by a generous National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant.

Read More